Tumor Treating Fields Improve Overall Survival for Patients With Advanced Non-Small Cell Lung Cancer
According to a press release published on January 5, 2023, by Novocure, results from the LUNAR study found that patients with platinum-resistant, stage 4 non-small cell lung cancer (NSCLC) experienced clinically meaningful and significant improvement in overall survival (OS) when treated with standard therapy plus Tumor Treating Fields (TTFields), compared with standard therapy alone.
Novocure noted that the last study to lead to significant improvement in OS in this patient population was published more than 6 years ago.
The pivotal, open-label, randomized LUNAR trial aimed to test the safety and efficacy of TTFields when used in combination with immune checkpoint inhibitors or docetaxel versus immune checkpoint inhibitors or docetaxel alone for patients with stage 4 NSCLC who progressed during or after platinum-based therapy. The primary end point of the trial was OS which, as Novocure announced, the study met.
Novocure expects to concurrently file a Premarket Approval application with the U.S. Food and Drug Administration (FDA) and a Conformite Europeenne (CE) Mark in the European Union in the second half of 2023.
The full results of the LUNAR study will be released at a future medical conference.
Source:
Novocure Announces Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint. Press Release. BusinessWire. January 5, 2023. Accessed January 5, 2023. https://www.businesswire.com/news/home/20230105005325/en/Novocure-Announces-Pivotal-LUNAR-Study-in-Non-Small-Cell-Lung-Cancer-Met-Primary-Overall-Survival-Endpoint
